Bristol-Myers Squibb Company (BMY) Q1 2026 (USD): EPS 1.58 (exp. 1.42), revenue 11.5bln (exp. 10.9bln). Reaffirms 2026 guidance with total revenue & adj. EPS trending toward upper end of ranges
Importance
Level 1
- Eliquis revenue 4.14bln, up 16%.
- FY worldwide Eliquis Revenue growth of 10% - 15%.